Search results
Is Merck & Co., Inc. (NYSE:MRK) the Best Dow Stock To Buy According to Hedge Funds?
Insider Monkey via Yahoo Finance· 18 hours agoWe recently identified the best dow stocks according to hedge funds. Even though Merck & Co., Inc....
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks· 6 days agoFree Report) boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for several types of cancer and alone accounting for more than 45% of the
Madison-based life science company Mirus Bio to be acquired for $600 million
Small Business Times· 3 days agoMadison-based Mirus Bio, a manufacturer of transfection regents used in gene therapies, has entered...
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology via Yahoo Finance· 2 days agoAccording to GlobalData’s Pharma Intelligence Center, petosemtamab is forecast to generate $713m in...
Lilly partners with Aktis, deepening radiopharma investment
BioPharma Dive via Yahoo Finance· 5 days agoMyers Squibb and Novartis, the latter of which has two approved radiopharmaceuticals, participated...
McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI
VentureBeat· 3 days agoAtropos Health, a healthcare technology company focused on generating personalized real-world...
‘It made my penis change shape’: Inside the hair loss drug controversy
The Telegraph via Yahoo News· 4 days agoA few years ago, James* was at the pub with colleagues when a female co-worker walked behind him to...
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Zacks· 4 days agoFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 5 days agoThe company already markets one, the breast cancer drug Enhertu, and has another now before...
Two local RNA-focused biotechs merge, plan to go public 'at some point' - Boston Business Journal
The Business Journals· 2 days agoMunshi has experience running larger public companies, having previously led Arena Pharmaceuticals...